Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 Oct 9;24:14081.
doi: 10.1038/npjpcrm.2014.81.

Cost-effectiveness of Initiating Extrafine- Or Standard Size-Particle Inhaled Corticosteroid for Asthma in Two Health-Care Systems: A Retrospective Matched Cohort Study

Affiliations
Free PMC article
Comparative Study

Cost-effectiveness of Initiating Extrafine- Or Standard Size-Particle Inhaled Corticosteroid for Asthma in Two Health-Care Systems: A Retrospective Matched Cohort Study

Richard J Martin et al. NPJ Prim Care Respir Med. .
Free PMC article

Abstract

Background: Real-life studies are needed to determine the cost-effectiveness of asthma therapies in clinical practice.

Aim: To compare the cost-effectiveness of extrafine-particle inhaled corticosteroid (ICS) with standard size-particle ICS in the United Kingdom (UK) and United States (US).

Methods: These retrospective matched cohort analyses used large electronic databases to study asthma-related outcomes for patients in the UK (12-60 years old; n=1730) and US (12-80 years; n=10,312) prescribed extrafine beclomethasone or fluticasone as their first ICS therapy for asthma. Patients were matched on demographic characteristics and asthma severity during 1 baseline year, and asthma control and asthma-related costs were compared during 1 outcome year.

Results: In both the UK and US, adjusted odds of risk-domain asthma control were similar, whereas the odds of overall control (no hospitalisation or oral steroids for asthma, no antibiotics for lower respiratory infection, limited reliever use) were greater for extrafine ICS in both countries (UK odds ratio, 1.23; 95% confidence interval (CI), 1.01-1.50). Asthma-related annual costs, adjusted for baseline, were significantly lower for extrafine-particle ICS cohorts in both countries (UK difference, -£66 (95% CI,-93 to -37)). Cost-effectiveness analyses using the two measures of asthma control found 92 and 98% probabilities of extrafine-particle ICS being the preferred treatment strategy (less costly and more effective than standard size-particle ICS) in the UK, and 84 and 100% probabilities in the US.

Conclusions: Initiating ICS therapy for asthma as extrafine-particle ICS seems the dominant treatment option (less costly and more effective) compared with standard size-particle ICS in both the UK and the US.

Figures

Figure 1
Figure 1
Study design. ICS, inhaled corticosteroid; pMDI, pressurised metered-dose inhaler.
Figure 2
Figure 2
UK Study: Cost-effectiveness planes for extrafine-particle ICS relative to standard size-particle ICS matched cohort (adjusted results): effectiveness based on (a) risk-domain asthma control and (b) overall control (risk and impairment). The horizontal axis divides probable costs (more expensive above, less expensive below) and the vertical axis divides the probable effectiveness (less on the left, more on the right).
Figure 3
Figure 3
US Study: Cost-effectiveness planes for extrafine-particle ICS relative to standard size-particle ICS matched cohort (adjusted results): effectiveness based on (a) risk-domain asthma control and (b) overall control (risk and impairment).

Similar articles

See all similar articles

Cited by 9 articles

See all "Cited by" articles

References

    1. Simpson CR, Sheikh A. Trends in the epidemiology of asthma in England: a national study of 333,294 patients. J R Soc Med. 2010;103:98–106. - PMC - PubMed
    1. Zahran HS, Bailey C, Garbe P. Vital signs: asthma prevalence, disease characteristics, and self-management education --- United States, 2001--2009. MMWR. 2011;60:547–552. - PubMed
    1. Meltzer EO, Blaiss MS, Nathan RA, Doherty DE, Murphy KR, Stoloff SW. Asthma burden in the United States: results of the 2009 Asthma Insight and Management survey. Allergy Asthma Proc. 2012;33:36–46. - PubMed
    1. Asthma UK. Asthma facts and FAQs , updated 2013. Available from http://www.asthma.org.uk/asthma-facts-and-statistics (accessed 14 January 2014).
    1. Barnett SB, Nurmagambetov TA. Costs of asthma in the United States: 2002–2007. J Allergy Clin Immunol. 2011;127:145–152. - PubMed

Publication types

MeSH terms

Substances

Feedback